A Phase 1/2 Study of Replicating Arenavirus-based Vector(s) Encoding Prostate Cancer-Associated Antigens in Participants with Metastatic Castration-Resistant Prostate Cancer
Contact:
NCT Number:
Protocol:
AAAU7983
Study Status:
Active/Enrolling
Population:
Adult
Phase:
I/II
The purpose of this study is to determine whether HB-302/HB-301 therapy is safe and well tolerated. This will be the first time HB-302/HB-301 will be tested in humans. HB-302/HB-301 has not yet been approved by the Food and Drug Administration (FDA)
Are you Eligible? (Inclusion Criteria)
- Must be 18 years old or older. - Cannot have COVID positive result 6 weeks prior to study enrollment. - Must agree to use contraception during the study and through 5 months after the last dose of study drug
Specialty Area(s)
Prostate Cancer, Immunotherapy
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
